REGN241206P860000
- 0.00
- 0.000.00%
Regeneron Pharmaceuticals Newsroom
Tuesday S&P 500, Nasdaq Pull Back From Highs | Live Stock
Regeneron Pharmaceuticals (NASDAQ:REGN) Shareholders Have Earned a 16% CAGR Over the Last Five Years
Maia Biotechnology, Regeneron Expand Clinical Supply Deal
Express News | Maia Biotechnology Inc - Expects New Patient Enrollment to Begin Soon
Express News | Maia Biotechnology Inc - Expansion of 2021 Clinical Supply Agreement for Phase 2 Trial
Medigene Receives Milestone Payment From Regeneron Pharmaceuticals, Inc.
S&P 500 and Nasdaq Hit Closing and Trading Highs Monday | Wall Street Today
December Starts With a Mixed Market | Live Stock
RBC Capital Remains a Buy on Regeneron (REGN)
Wednesday Ends With Index Decline | Wall Street Today
Dow Hits Another Record, Core PCE 2.8% as Expected | Live Stock
Regeneron Pharmaceuticals Insiders Sold US$38m Of Shares Suggesting Hesitancy
Sanofi (SNY.US)/Regeneron (REGN.US) Dupilumab Injection approved again for clinical treatment of pure moss disease in China
A new clinical trial implied consent has been granted for the duperimabd injection declared by Sanofi (SNY.US).
S&P 500, Dow Hit Records, Trump Tariffs to Cost Hundreds of Billions | Wall Street Today
Regeneron Pharmaceuticals Unusual Options Activity
Dow Falls After Record, Trump Talks Tariffs on Day One | Live Stock
Do Wall Street Analysts Like Regeneron Pharmaceuticals Stock?
Intellia Therapeutics' Nex-z Receives FDA Regenerative Medicine Advanced Therapy Designation
S&P 500, Dow Hit Records Right After Open | Live Stock
Do Options Traders Know Something About Regeneron (REGN) Stock We Don't?